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Clinical PerspectiveWhat Is New?Frail patients receive lower rates of invasive cardiac care during hospitalization for myocardial infarction.Increased frailty is independently associated with increased postdischarge all‐cause mortality but not cardiac‐specific mortality.What Are the Clinical Implications?Older patients should be screened for frailty routinely during index hospitalization for myocardial infarction.Additional use of invasive cardiac therapies alone may not necessarily be sufficient to improve prognosis for frail patients.Management of noncardiac risk both during index hospitalization and after discharge presents a valuable opportunity to improve care and outcomes for this high‐risk population.

Introduction {#jah33497-sec-0008}
============

*Frailty* is defined as state of susceptibility in which a person has decreased physical reserve that leads to a greater likelihood of an adverse outcome when a stressor is applied.[1](#jah33497-bib-0001){ref-type="ref"} The overall prevalence of frailty in adults aged ≥65 years has been estimated at ≈10%. However, in patients with significant cardiovascular disease, the prevalence may be as high as 60%.[2](#jah33497-bib-0002){ref-type="ref"} Frailty has been associated with increased major adverse cardiac events after myocardial infarction (MI).[3](#jah33497-bib-0003){ref-type="ref"}, [4](#jah33497-bib-0004){ref-type="ref"}, [5](#jah33497-bib-0005){ref-type="ref"}, [6](#jah33497-bib-0006){ref-type="ref"} Mechanisms proposed for worse outcomes are likely multifactorial. Compared with nonfrail patients, frail patients have delayed recognition of the symptoms delayed recognition of the symptoms and contact with medical care, less ability to adhere to medical treatment, risk of delirium with polypharmacy, and therapeutic nihilism toward invasive procedures. Understanding the impact of frailty on therapy selection and outcomes, particularly invasive therapies, is an important consideration in the context of a rapidly aging population with increasing medical complexity.[7](#jah33497-bib-0007){ref-type="ref"} Although technical and procedural innovations have expanded the therapeutic armamentarium available to treat patients, many of these therapies have not been explicitly tested in older frail patients. Consequently, at the bedside, there is limited guidance on whether and how metrics of frailty should be applied to influence risk--benefit decision‐making for utilization of these interventions. The CONCORDANCE (Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence, and Clinical Events) registry presents an opportunity to evaluate the clinical characteristics, treatments, and outcomes of patients according to baseline frailty status on presentation at the hospital. In this study, we utilized the CONCORDANCE registry database to report the prevalence of frailty in older adults presenting with MI using a frailty index (FI) (deficit accumulation model). We specifically sought to explore the association of frailty in older MI populations with the use of evidence‐based therapies and outcomes after MI.

Methods {#jah33497-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Data Source and Analysis Population {#jah33497-sec-0010}
-----------------------------------

All patients aged ≥65 years with ST‐segment--elevation MI (STEMI) or non‐STEMI (NSTEMI) in the CONCORDANCE registry from 2009 to 2016 were included in the initial study population (n=5006 from 41 hospitals). CONCORDANCE (ACTRN12614000887673), a prospective, Australian registry of MI patients, was designed within a comparative effectiveness research framework to collect and report data from hospitals located in geographically diverse regions of Australia and has been described previously.[8](#jah33497-bib-0008){ref-type="ref"} Information including patient demographics, presenting characteristics, past medical history, in‐hospital management, and outcomes after discharge were entered into a Web‐based database using an electronic clinical record form. Because data were primarily at the local site for quality improvement, an opt‐out consent process was applied with a consent waiver for patients who were too ill to provide informed consent. Patients could be enrolled in the registry only once over a 12‐month period. All participating hospitals secured institutional review board approval. Approval for this analysis was granted by the lead ethics committee, Concord Hospital, Sydney Local Health district.

Frailty Assessment {#jah33497-sec-0011}
------------------

Twenty‐eight variables were identified from the baseline data (see Table [1](#jah33497-tbl-0001){ref-type="table"}) to construct a FI using a deficit accumulation model, as described previously.[9](#jah33497-bib-0009){ref-type="ref"}, [10](#jah33497-bib-0010){ref-type="ref"} In brief, variables in a FI can be diseases or comorbidities, symptoms, signs, or laboratory measures, with each being age‐related; not saturating too early (ie, not found in all individuals early on); associated with adverse outcomes; and, as a group, covering several bodily systems. Dichotomous variables (eg, presence of hypertension) were coded as 0 for absent and 1 for present. Dichotomous scores were assigned for continuous variables as appropriate. For number of cardiovascular medications, for example, ≥3 medications were coded as 1 and \<3 medications were coded as 0. Each participant received a score between 0 and 28, and the FI was defined as the frailty score divided by 28, ranging between 0 and 1. While frailty in the deficit accumulation model is a continuum, similar prior analyses[3](#jah33497-bib-0003){ref-type="ref"} have stratified patients into 2 groups: (1) *frail*, defined as a FI ≥0.25 (ie, frailty score ≥7) and (2) *nonfrail*, defined as a FI \<0.25 (ie, frailty score \<7).

###### 

Frailty Index Parameters

  Variable                                           Scoring on Index
  -------------------------------------------------- -----------------------------
  Weight \<60 kg                                     Yes=1, No=0
  Previous MI                                        Yes=1, No=0
  Previous angiogram positive for coronary disease   Yes=1, No=0
  Previous CHF                                       Yes=1, No=0
  Previous PCI                                       Yes=1, No=0
  Previous coronary bypass surgery                   Yes=1, No=0
  Previous AF                                        Yes=1, No=0
  Previous DVT/PE                                    Yes=1, No=0
  Previous major bleed                               Yes=1, No=0
  Permanent pacemaker                                Yes=1, No=0
  ICD                                                Yes=1, No=0
  Chronic renal failure                              Yes=1, No=0
  Dialysis                                           Yes=1, No=0
  Previous stroke or TIA                             Yes=1, No=0
  Diabetes mellitus                                  Yes=1, No=0
  Hypertension                                       Yes=1, No=0
  Dyslipidemia                                       Yes=1, No=0
  Smoking history                                    Active=1, Former or Never=0
  PAD                                                Yes=1, No=0
  Dementia/cognitive impairment                      Yes=1, No=0
  Impaired mobility                                  Yes=1, No=0
  Incontinence                                       Yes=1, No=0
  Liver disease                                      Yes=1, No=0
  Lung disease                                       Yes=1, No=0
  Cancer limiting life expectancy                    Yes=1, No=0
  Polypharmacy (≥3 cardiovascular medications)       Yes=1, No=0
  Hb \<100 g/L                                       Yes=1, No=0
  Prior mechanical valve replacement                 Yes=1, No=0

AF indicates atrial fibrillation; CHF, congestive heart failure; DVT/PE, deep vein thrombosis/pulmonary embolism; ICD, implantable cardioverter‐defibrillator; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

Statistical Analysis {#jah33497-sec-0012}
--------------------

Continuous variables are reported as medians with 25th and 75th percentiles and compared using the Wilcoxon rank‐sum test. Categorical variables are presented as proportions and compared using the χ^2^ test. Baseline demographics, presentation characteristics, in‐hospital management including invasive and medical therapy, and in‐hospital outcomes (all‐cause mortality, cardiac‐specific mortality, and major bleeding) stratified by MI type (STEMI and NSTEMI) were compared between the 2 frailty groups.

Cardiac‐specific mortality was defined as death due to MI, arrhythmia, cardiac rupture, cardiogenic shock, or other cardiac reasons provided by free text and adjudicated by the CONCORDANCE management committee. *Major bleeding* was defined as having intracranial bleeding, retroperitoneal bleeding, intraocular bleeding, gastrointestinal/genitourinary bleeding requiring intervention, (endoscopy/transfusion) or cessation of therapies, access‐site hemorrhage requiring radiological or surgical intervention, ≥5‐cm‐diameter hematoma at puncture site, reoperation for bleeding, bleeding leading to a prolongation of hospitalization, decrease in Hb \>2 g/dL in the presence of a bleeding source, decrease in Hb \>3 g/dL in the absence of a bleeding source, or any bleeding event requiring a blood or blood product transfusion. Among patients discharged alive from the index hospitalization, clinical outcomes including all‐cause and cardiac‐specific mortality and rehospitalization for heart cause at 6 months were evaluated.

We then evaluated whether FI is a predictor of in‐hospital all‐cause and cardiac‐specific mortality. The generalized estimating equation method with an exchangeable working correlation structure was used to account for within‐site clustering of patients (ie, within‐site correlation for response).[11](#jah33497-bib-0011){ref-type="ref"} Multivariable logistic regression models were used to estimate the marginal effect of FI separately by MI type (NSTEMI and STEMI) after adjusting for age, sex, and covariates previously identified as significantly associated with in‐hospital mortality among patients with MI.[12](#jah33497-bib-0012){ref-type="ref"} These covariates include heart failure on presentation, cardiogenic shock, heart rate, systolic blood pressure, cardiac arrest, creatinine clearance, and initial troponin (as a ratio of the upper limit of normal). Finally, we evaluated whether FI is a predictor of 6‐month all‐cause and cardiac‐specific mortality. Multivariable logistic regression models were used to estimate the marginal effect of FI separately by MI type (NSTEMI and STEMI) after adjusting for sex and GRACE (Global Registry of Acute Coronary Events) risk score.[13](#jah33497-bib-0013){ref-type="ref"}, [14](#jah33497-bib-0014){ref-type="ref"} Odds ratios (ORs) with 95% confidence intervals (CIs) were reported per 0.1 FI. A value of *P*\<0.05 was considered significant for all tests. All statistical analyses were performed by the CONCORDANCE group within the ANZAC Institute with SAS software (v9.4; SAS Institute).

Results {#jah33497-sec-0013}
=======

The study population comprised 3944 patients; 1275 had STEMI, and 2669 had NSTEMI.

STEMI Patients {#jah33497-sec-0014}
--------------

Frailty score distribution among the STEMI patients is shown in Figure [1](#jah33497-fig-0001){ref-type="fig"}A; the median FI was 0.11 (interquartile range; 0.04--0.18); 192 (15%) patients were considered frail. Compared with nonfrail counterparts, frail patients were older and had more cardiac and noncardiac comorbidities, cognitive impairment, impaired mobility, incontinence, and wish for no resuscitation (Table [2](#jah33497-tbl-0002){ref-type="table"}). Frail patients also had lower left ventricular function and more cardiac arrest and congestive heart failure on presentation (Table [3](#jah33497-tbl-0003){ref-type="table"}).

![Frailty index distribution among patients with (A) STEMI (ST‐segment--elevation myocardial infarction) (B) NSTEMI (non‐ST‐segment--elevation myocardial infarction).](JAH3-7-e009859-g001){#jah33497-fig-0001}

###### 

Patient Characteristics

                                                                  STEMI                  NSTEMI                                                                         
  --------------------------------------------------------------- ---------------------- ---------------------- --------- ---------------------- ---------------------- ---------
  Demographics                                                                                                                                                          
  Age, y                                                          72 (68--79)            78 (71--84)            \<0.001   74 (69--80)            77 (71--83)            \<0.001
  Sex, male                                                       732 (67.6)             133 (69)               0.38      1114 (63)              624 (69.2)             0.004
  Weight, kg                                                      78 (68--87)            75 (62--87)            0.37      78 (68--90)            79 (68--92)            0.49
  Private health insurance                                        322 (29.7)             42 (21.8)              0.001     459 (26)               189 (21)               0.01
  Regular general practitioner / healthcare provider              978 (90.3)             184 (95.8)             0.18      1648 (93.2)            855 (94.8)             0.11
  Past medical history                                                                                                                                                  
  Prior MI                                                        94 (8.7)               127 (66.1)             \<0.001   297 (16.8)             676 (74.9)             \<0.001
  Prior HF                                                        26 (2.4)               45 (23.4)              \<0.001   74 (4.2)               292 (32.4)             \<0.001
  Previous angiogram identifying coronary disease                 96 (8.7)               133 (69.3)             \<0.001   362 (20.5)             726 (80.5)             \<0.001
  Previous PCI                                                    61 (5.6)               84 (43.8)              \<0.001   147 (8.3)              419 (46.5)             \<0.001
  Previous CABG                                                   14 (1.3)               51 (26.6)              \<0.001   141 (8)                340 (37.7)             \<0.001
  Previous AF                                                     69 (6.4)               54 (28.1)              \<0.001   200 (11.3)             276 (30.6)             \<0.001
  Previous DVT/PE                                                 30 (2.8)               21 (10.9)              \<0.001   61 (3.5)               91 (10.1)              \<0.001
  Previous major bleed                                            9 (0.8)                12 (6)                 \<0.001   34 (1.9)               52 (5.8)               \<0.001
  Previous metal valve replacement                                3 (0.3)                4 (2.1)                0.002     10 (0.6)               23 (2.5)               \<0.001
  Permanent pacemaker                                             8 (0.7)                13 (6.8)               \<0.001   36 (2)                 100 (11.1)             \<0.001
  ICD                                                             4 (0.4)                3 (1.6)                0.01      5 (0.3)                27 (3)                 \<0.001
  Chronic renal failure                                           37 (3.4)               59 (30.7)              \<0.001   106 (6)                285 (31.6)             \<0.001
  Previous stroke/TIA                                             61 (5.6)               46 (24)                \<0.001   113 (6.4)              199 (22.1)             \<0.001
  Diabetes mellitus                                               207 (19.1)             93 (48.4)              \<0.001   422 (23.9)             480 (53.2)             \<0.001
  Hypertension                                                    625 (57.7)             169 (88)               \<0.001   1169 (66.2)            819 (90.8)             \<0.001
  Dyslipidemia                                                    453 (41.8)             157 (81.8)             \<0.001   925 (52.3)             759 (84.1)             \<0.001
  Smoking history                                                                                               0.15                                                    0.01
  Never smoked                                                    507 (46.8)             76 (39.6)                        796 (45)               368 (40.8)             
  Ex‐smoker                                                       372 (34.3)             79 (41.1)                        796 (45)               417 (46.2)             
  Current smoker                                                  199 (18.4)             36 (18.8)                        167 (9.5)              115 (12.7)             
  PAD                                                             38 (3.5)               35 (18.2)              \<0.001   94 (5.3)               193 (21.4)             \<0.001
  Dementia/cognitive impairment                                   28 (2.6)               28 (14.6)              \<0.001   45 (2.5)               95 (10.5)              \<0.001
  Impaired mobility                                               65 (6)                 66 (34.4)              \<0.001   133 (7.5)              292 (32.4)             \<0.001
  Incontinence                                                    26 (2.4)               28 (14.6)              \<0.001   36 (2)                 85 (9.4)               \<0.001
  Liver disease                                                   15 (1.4)               1 (0.5)                0.35      20 (1.1)               34 (3.7)               0.001
  Lung disease                                                    109 (10)               55 (28.6)              \<0.001   206 (11.7)             242 (26.8)             \<0.001
  Cancer limiting life expectancy                                 31 (2.9)               13 (6.8)               0.01      40 (2.2)               37 (4.1)               \<0.001
  Not for resuscitation                                           61 (5.6)               39 (20.3)              \<0.001   62 (3.5)               112 (12.4)             \<0.001
  Polypharmacy (≥3 cardiovascular medications) before admission   158 (15)               131 (68)               \<0.001   495 (28)               719 (80)               \<0.001
  GRACE risk score                                                132.0 (120.4--148.6)   147.6 (133.2--170.8)   \<0.001   121.7 (106.6--138.2)   133.7 (117.9--150.1)   \<0.001

Data are shown as median (interquartile range) or number (percentage). AF indicates atrial fibrillation; CABG, coronary artery bypass grafting; DVT/PE, deep vein thrombosis/pulmonary embolism; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; ICD, implantable cardioverter‐defibrillator; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; TIA, transient ischemic attack.

###### 

Presentation Characteristics and In‐Hospital Management

  Variable                                             STEMI            NSTEMI                                                         
  ---------------------------------------------------- ---------------- ------------------ --------- ---------------- ---------------- ---------
  Presentation characteristics                                                                                                         
  Ambulance called                                     681 (62.8)       139 (72.4)         0.003     967 (54.7)       612 (67.8)       \<0.001
  Heart rate, beats/min                                75 (64--89)      80 (66--98)        0.003     79 (67--92)      81 (68--96)      0.002
  SBP, mm Hg                                           135 (117--154)   137 (111--155)     0.50      140 (124--160)   140 (123--158)   0.10
  Killip class                                                                             \<0.001                                     \<0.001
  1                                                    950 (87.7)       136 (70.8)                   1543 (87.3)      619 (68.6)       
  2                                                    100 (9.2)        29 (15.1)                    178 (10.1)       226 (25.1)       
  3                                                    20 (1.8)         14 (7.3)                     42 (2.4)         50 (5.5)         
  4                                                    13 (1.2)         13 (6.8)                     4 (0.2)          7 (0.8)          
  Cardiac arrest on admission                          92 (8.5)         24 (12.5)          0.10      29 (1.6)         22 (2.4)         
  Hb \<100 g/L                                         20 (1.8)         23 (12.0)          \<0.001   55 (3.1)         111 (12.3)       \<0.001
  Ratio of initial creatinine/ULN                      0.8 (0.7--1.0)   1.1 (0.8--1.5)     \<0.001   0.8 (0.7--1.0)   1.0 (0.8--1.4)   0.54
  In‐hospital management                                                                                                               
  Echocardiogram                                       816 (75.3)       133 (69.3)         0.11      1039 (58.8)      444 (40.2)       \<0.001
  LV function[a](#jah33497-note-0004){ref-type="fn"}                                       0.01                                        \<0.001
  Normal                                               211 (25.8)       26 (19.5)                    606 (58.3)       165 (37.3)       
  Mild impairment                                      178 (21.8)       26 (19.5)                    184 (17.7)       71 (16.0)        
  Moderate impairment                                  175 (21.4)       35 (26.3)                    143 (13.8)       76 (17.1)        
  Severe impairment                                    53 (6.5)         19 (14.2)                    54 (5.2)         61 (13.7)        
  Intra‐aortic balloon pump                            45 (4.2)         4 (2.1)            0.15      23 (1.3)         8 (0.9)          0.37
  Ventilation                                          93 (8.6)         26 (13.5)          0.01      99 (5.6)         36 (2.9)         0.06
  Cardiac catheterization                              999 (92.2)       142 (74.0)         \<0.001   1479 (83.7)      530 (58.8)       \<0.001
  Thrombolysis                                         340 (31.4)       36 (18.8)          \<0.001   NA               NA               NA
  First medical contact to lysis time, min             63 (43--95)      90 (62--139)       0.01      NA               NA               NA
  Symptom onset to lysis time, h                       2.7 (1.6--5.0)   3.2 (2.0--5.6)     0.16      NA               NA               NA
  Primary PCI                                          528 (48.7)       68 (35.4)          0.007     NA               NA               NA
  First medical contact to primary PCI time, min       127 (91--262)    156.5 (118--349)   0.03      NA               NA               NA
  Symptom onset to primary PCI time, h                 3.8 (2.4--9.9)   4.4 (2.7--13.4)    0.48      NA               NA               NA
  PCI                                                  773 (71.4)       101 (52.6)         \<0.001   688 (38.9)       228 (25.3)       \<0.001
  CABG                                                 90 (8.3)         7 (3.6)            0.01      218 (12.3)       58 (6.4)         \<0.001
  Revascularization (PCI or CABG)                      936 (86.4)       129 (67.2)         \<0.001   904 (51.2)       284 (31.5)       \<0.001
  Reperfusion (primary PCI or thrombolysis)            822 (75.9)       102 (53.1)         \<0.001   NA               NA               NA
  Referral to cardiac rehabilitation                   815 (75.3)       94 (49)            \<0.001   1118 (63.3)      435 (48.2)       \<0.001

Data are shown as median (interquartile range) or number (percentage). CABG indicates coronary artery bypass grafting; LV, left ventricular; NA, not applicable; NSTEMI, non--ST‐segment--elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST‐segment--elevation myocardial infarction; ULN, upper limit of normal.

LV function was determined among patients undergoing echocardiogram.

Use of fibrinolysis, cardiac catheterization, primary percutaneous coronary intervention, and revascularization overall, both percutaneous coronary intervention and coronary artery bypass grafting, was significantly lower among frail patients (Table [3](#jah33497-tbl-0003){ref-type="table"}). Among patients treated with primary percutaneous coronary intervention or fibrinolysis, duration from first medical contact to reperfusion therapy was significantly longer among frail patients. In‐hospital use of aspirin, ADP receptor inhibitors, β‐blockers, angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, and statins was lower among frail patients (Figure [2](#jah33497-fig-0002){ref-type="fig"}). Among patients discharged from the hospital, however, use of only aspirin (not other cardiac medications) was lower among frail patients (Figure [3](#jah33497-fig-0003){ref-type="fig"}); frail patients were more likely to be treated with anticoagulants at discharge. At discharge, referral to cardiac rehabilitation was 34% lower among frail patients.

![In‐hospital medical therapy by frailty classification among patients with ST‐segment--elevation myocardial infarction. \**P*\<0.05. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; LMWH, low‐molecular‐weight heparin.](JAH3-7-e009859-g002){#jah33497-fig-0002}

![Discharge medical therapy by frailty classification among patients with ST‐segment--elevation myocardial infarction. \**P*\<0.05. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.](JAH3-7-e009859-g003){#jah33497-fig-0003}

### Clinical outcomes {#jah33497-sec-0015}

All‐cause and cardiac‐specific mortality in hospital and major bleeding were higher among frail patients (Table [4](#jah33497-tbl-0004){ref-type="table"}). After adjustment, the FI was significantly associated with higher all‐cause in‐hospital mortality (OR: 1.38 per 0.1 FI; 95% CI, 1.05--1.83; *P*=0.02) but not cardiac‐specific in‐hospital mortality (OR: 0.54 per 0.1 FI; 95% CI, 0.24--1.21; *P*=0.13). Among patients discharged from the hospital, rates of all‐cause and cardiac‐specific mortality and readmission for heart disease were higher among frail patients at 6 months. After adjustment, the FI was associated with higher 6‐month all‐cause mortality (OR: 1.74 per 0.1 FI; 95% CI, 1.37--2.22; *P*\<0.001) but not cardiac‐specific mortality (OR: 1.00 per 0.1 FI; 95% CI, 0.53--1.90; *P*=0.99).

###### 

In‐hospital and 6‐Month Postdischarge Outcomes for STEMI and NSTEMI Patients

                                        Nonfrail     Frail        *P* Value
  ------------------------------------- ------------ ------------ -----------
  In‐hospital outcomes                                            
  STEMI (n)                             1083         192          
  All‐cause death                       90 (8.3)     46 (24)      \<0.001
  Death due to cardiac causes           81 (7.5)     39 (20.3)    0.52
  Major bleeding                        110 (10.2)   30 (15.6)    0.02
  NSTEMI (n)                            1767         902          
  All‐cause death                       50 (2.8)     63 (7)       \<0.001
  Death due to cardiac causes           43 (2.4)     52 (5.8)     0.59
  Major bleeding                        180 (10.2)   107 (11.9)   0.29
  Six‐month postdischarge outcomes                                
  STEMI (n)                             810          117          
  All‐cause mortality                   27 (3.3)     15 (12.8)    \<0.001
  Death due to a cardiac cause          11 (1.4)     7 (6.0)      \<0.001
  Rehospitalization for heart disease   158 (19.5)   34 (29.1)    0.01
  NSTEMI (n)                            1373         619          
  All‐cause mortality                   54 (3.9)     78 (12.6)    \<0.001
  Death due to cardiac cause            16 (1.2)     20 (3.2)     \<0.001
  Rehospitalization for heart disease   278 (20.2)   182 (29.4)   \<0.001

Data are shown as number (percentage) except as noted. NSTEMI indicates non--ST‐segment--elevation myocardial infarction; STEMI, ST‐segment--elevation myocardial infarction.

NSTEMI Patients {#jah33497-sec-0016}
---------------

Frailty score distribution among the NSTEMI patients is shown in Figure [1](#jah33497-fig-0001){ref-type="fig"}B; the median FI was 0.18 (interquartile range: 0.11--0.25); 902 (34%) patients were considered frail. Compared with nonfrail NSTEMI patients, frail NSTEMI patients were older and had more cardiac and noncardiac comorbidities, cognitive impairment, impaired mobility, incontinence, and wish for no resuscitation (Table [2](#jah33497-tbl-0002){ref-type="table"}). Frail patients also had lower left ventricular function and more congestive heart failure on presentation (Table [3](#jah33497-tbl-0003){ref-type="table"}).

Use of cardiac catheterization, percutaneous coronary intervention, and coronary artery bypass grafting were significantly lower among frail patients (Table [3](#jah33497-tbl-0003){ref-type="table"}). In‐hospital use of aspirin and ADP receptor inhibitor, but not other secondary cardiac medications, was lower among frail patients (Figure [4](#jah33497-fig-0004){ref-type="fig"}). Among patients discharged from the hospital, use of aspirin was lower, but use of ADP receptor inhibitors was higher among frail patients (Figure [5](#jah33497-fig-0005){ref-type="fig"}). At discharge, referral to cardiac rehabilitation was 23% lower among frail patients.

![In‐hospital medical therapy by frailty classification among patients without ST‐segment--elevation myocardial infarction. \**P*\<0.05. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; LMWH, low‐molecular‐weight heparin.](JAH3-7-e009859-g004){#jah33497-fig-0004}

![Discharge medical therapy by frailty classification among patients without ST‐segment--elevation myocardial infarction. \**P*\<0.05. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.](JAH3-7-e009859-g005){#jah33497-fig-0005}

### Clinical outcomes {#jah33497-sec-0017}

All‐cause and cardiac‐specific in‐hospital mortality rates were higher among frail patients (Table [4](#jah33497-tbl-0004){ref-type="table"}). There was no difference in major bleeding. After adjustment, the FI remained significantly associated with higher all‐cause in‐hospital mortality (OR: 1.49 per 0.1 FI; 95% CI, 1.34--1.95; *P*=0.004) but not cardiac‐specific in‐hospital mortality (OR: 1.10 per 0.1 FI; 95% CI, 0.66--1.85; *P*=0.71). Among patients discharged from the hospital, all‐cause and cardiac mortality and readmission for heart disease were higher among frail patients at 6 months. After adjustment, the FI was associated with higher 6‐month all‐cause mortality (OR: 1.62 per 0.1 FI; 95% CI, 1.40--1.87; *P*\<0.001) but not cardiac‐specific mortality (OR: 1.01 per 0.1 FI; 95% CI, 0.78--1.32; *P*=0.93).

Discussion {#jah33497-sec-0018}
==========

In this large, contemporary evaluation of treatment and outcomes of older MI patients, several important observations regarding prevalence and outcomes associated with frailty emerge. Compared with nonfrail patients, frail patients presenting with MI receive less medical and invasive in‐hospital care including diagnostic angiography, reperfusion therapy, and coronary revascularization. Referral to rehabilitation at discharge was also lower among frail patients. Although in‐hospital and postdischarge all‐cause and cardiac‐specific mortality was significantly greater among frail patients, after adjustment, frailty remained significantly associated with increased in‐hospital and 6‐month all‐cause mortality but not cardiac‐specific mortality. These findings reinforce that presence of frailty identifies patients who are at increased risk of death after MI. However, additional cardiac interventions---including invasive coronary interventions alone---may not necessarily be sufficient to improve the prognosis of this high‐risk population. Improving the outcomes of this patient population will require understanding MI presentation in the context of other conditions and patient goals of care. It also requires addressing noncardiac reasons for mortality during and after hospitalization for MI.

Our study adds to the growing body of evidence on the implications of frailty in cardiovascular medicine. Frailty is of high priority given aging and the increasingly complex nature of cardiovascular patients. There is no gold standard for frailty assessment, with upward of 20 tools that have been developed to measure frailty.[15](#jah33497-bib-0015){ref-type="ref"} Phenotypic assessment of frailty can be difficult in patients with acute illness and, in general, predicts mortality less well than measures that consider \>5 deficits.[16](#jah33497-bib-0016){ref-type="ref"} Dodson et al demonstrated that gait speed, a component of the frailty phenotype, measured 1 month after MI was associated with a 2‐fold increase in mortality at 1 year, but its significance independent of clinical factors was unclear.[17](#jah33497-bib-0017){ref-type="ref"} As such, in the present study we employed the health deficit accumulation method to assess for frailty. This approach recognizes that frailty is a continuum---it is not all or none; the more deficits a person has, across more organ systems and physiologic parameters, the more likely that person is to be frail. Although the idea and approach are relatively simple, the results yielded by the FI have been consistent across many settings, even though not every FI considers the same deficits, or even the same number of deficits.[10](#jah33497-bib-0010){ref-type="ref"}, [18](#jah33497-bib-0018){ref-type="ref"}, [19](#jah33497-bib-0019){ref-type="ref"} The prognostic implications of FI have been demonstrated not only in a variety of different chronic conditions (osteoporosis,[20](#jah33497-bib-0020){ref-type="ref"} human immunodeficiency virus and AIDS,[21](#jah33497-bib-0021){ref-type="ref"} kidney disease[22](#jah33497-bib-0022){ref-type="ref"}) but also in acute disease states (trauma[23](#jah33497-bib-0023){ref-type="ref"}).

In patients with significant cardiovascular disease, the prevalence of frailty has been shown to be as high as 60%.[2](#jah33497-bib-0002){ref-type="ref"} In this study of older Australian MI patients, 15% of STEMI patients and 34% of NSTEMI patients were classified as frail. In addition to greater cardiac and noncardiac comorbidities, frail patients had greater deficits in cognition, mobility, and continence. Our findings demonstrating that frailty is not only associated with increased in‐hospital but also midterm all‐cause mortality and hospitalizations following MI are consistent with prior analyses.[3](#jah33497-bib-0003){ref-type="ref"}, [4](#jah33497-bib-0004){ref-type="ref"}, [5](#jah33497-bib-0005){ref-type="ref"}, [6](#jah33497-bib-0006){ref-type="ref"} Despite this higher risk, frail patients were managed less aggressively compared with their nonfrail counterparts. Frail STEMI patients received 30% less reperfusion therapy and 22% less revascularization during index hospitalization. In‐hospital use of aspirin, ADP receptor inhibitors, and other secondary prevention medications was also lower among frail patients. Findings were similar among frail NSTEMI patients who received 30% less diagnostic angiography and 39% less revascularization compared with nonfrail NSTEMI patients. This treatment‐risk gap, in which evidence‐based invasive and pharmacological therapies are, paradoxically, used less often in higher risk patients has been observed previously.[24](#jah33497-bib-0024){ref-type="ref"} Elimination of this treatment‐risk paradox has been advocated to fully realize the benefits of these therapies in high‐risk patients.[25](#jah33497-bib-0025){ref-type="ref"} Nevertheless, more often than not, including in our database, the reasons why certain evidence‐based therapies were not offered are not ascertained. Furthermore, such patients are often not included in clinical trials of these therapies. Consequently, uncertainty remains about whether the overall outcomes of such frail patients who did not receive these therapies can be improved with increased their use.

We found that after adjustment for traditional factors associated with increased mortality after MI, frailty identified patients at increased risk of all‐cause, but not cardiac‐specific, mortality in hospital and after discharge, likely due to increased risk of competing noncardiac causes of death. Efforts to mitigate the treatment‐risk paradox in such patients with additional use of invasive cardiac therapies alone may not necessarily be sufficient to improve prognosis. Management of frail patients with numerous health deficits is complex. In addition to identifying increased risk of cardiac mortality, FI, as determined by the accumulation of such health deficits that are easy to assess at the bedside, identifies patients at increased risk of noncardiac death after MI. Such patients may benefit from more comprehensive care (eg, geriatrics consultation, prevention of delirium and deconditioning) during hospital admission for MI and close follow‐up after discharge. Compared with nonfrail counterparts, referral to rehabilitation was 34% and 23% lower for frail STEMI and NSTEMI patients, respectively. The benefit of multidisciplinary cardiac rehabilitation in terms of exercise capacity, obesity indexes, behavioral characteristics, and quality of life has been demonstrated in elderly patients.[26](#jah33497-bib-0026){ref-type="ref"}, [27](#jah33497-bib-0027){ref-type="ref"} Consequently, routine screening and identification of frailty during hospitalization for MI and management of noncardiac risk both during index hospitalization and after discharge present valuable opportunities to improve care for this high‐risk population. Inclusion of frail patients in future studies of cardiac therapies will also inform how best to use such therapies in these patients.

Limitations {#jah33497-sec-0019}
-----------

Several limitations should be considered. Although it has been suggested that at least 30 variables be included in the FI,[9](#jah33497-bib-0009){ref-type="ref"} in the present study, the available number of candidate variables was 28; however, a variety of deficits were incorporated covering health attitudes and practices, function, comorbidity, and physical performance. Data were not available for frailty phenotype, in which frailty is defined as a clinical syndrome displaying ≥3 of the following criteria: unintentional weight loss, exhaustion, slow walking speed, low physical activity, and weakness.[28](#jah33497-bib-0028){ref-type="ref"} Although the 2 approaches are conceptually similar, it has been shown that, at least when analyzed as a continuous variable, the FI can more precisely discriminate risk of death as well as measure change after an intervention.[15](#jah33497-bib-0015){ref-type="ref"} Data were self‐reported with the associated potential for inaccuracy. The data source also lacks precision regarding contraindications and reasons (eg, patient preference) for not using individual medications and procedures. Factors beyond those captured on the data collection form may represent unmeasured confounders that contributed to the discrepancy in therapies provided to frail patients; future registries should collect data on reasons why certain therapies are not used in individual patients.

Conclusion {#jah33497-sec-0020}
==========

In a contemporary cohort of Australian MI patients, ≈1 in 6 older STEMI patients and 1 in 3 older NSTEMI patients are frail. Frail patients receive less medical and invasive cardiac care during index hospitalization. After adjustment for traditional factors associated with increased risk for mortality after MI, increased frailty was associated with increased in‐hospital and midterm postdischarge all‐cause, but not cardiac‐specific, mortality. These findings help inform clinicians pay particular attention to and manage competing noncardiac risk in frail patients with MI.
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